<DOC>
	<DOCNO>NCT02720796</DOCNO>
	<brief_summary>Patients recurrent metastatic sarcoma consent develop patient derive xenograft ( PDX TumorGraft ) model tumor perform drug sensitivity test . The purpose study evaluate accuracy patient derive xenograft ( PDX ) model predict patient clinical response drug treatment .</brief_summary>
	<brief_title>Patient-Derived Xenograft ( PDX ) Modeling Adult Patients With Metastatic Recurrent Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>15 year age old Patients metastatic sarcoma one prior systemic treatment metastatic disease Patients recurrent sarcoma relapse Patients confirm histological diagnosis sarcoma suspect diagnosis sarcoma . Some specific subtypes sarcoma NOT eligible ( Gastrointestinal Stromal Tumor ( GIST ) , carcinosarcoma , sarcomatoid mesothelioma , metastatic phyllode tumor ) If initial suspect diagnosis sarcoma , must sarcoma diagnosis confirm prior proceed PDX drug sensitivity test Must measureable disease compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) evaluation follow biopsy surgery obtain tissue PDX development . No plan concurrent chemoradiation , target lesion use drug treatment correlation PDX Fresh tumor tissue available PDX development Eastern Cooperative Oncology Group performance status 01 Life expectancy exceed 6 month Plan receive systemic therapy Informed consent</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PDX</keyword>
	<keyword>TumorGraft</keyword>
	<keyword>Patient derive xenograft</keyword>
	<keyword>sarcoma</keyword>
</DOC>